Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Optomed’s Financial Statements Bulletin will be published on 15 February 2024

Optomed Plc Press Release 8 February 2024 at 9.00, Helsinki Optomed’s Financial Statements Bulletin will be published on 15 February 2024 Optomed will publish its Financial Statements Bulletin 2023 on 15 February 2023 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance by email

Transcom Holding AB (publ): Invitation to Transcom’s Q4 2023 results presentation webcast

Transcom are pleased to invite you to their Q4 2023 financial update webcast on Thursday, February 22, at 9:00 am CET, following the release of Q4 2023 results at 8:00 am CET. The Q4 report and presentation will be available on https://www.transcom.com/global/about-us/investor-relations. Presentation details Date/Time: Thursday, February 22, at 9:00 am CET Online Registration link: https://app.livestorm.co/transcom-holding/transcom-holding-ab-q4-2023-results-presentation   Important note: Please register via the link above at least 5-10 minutes prior the webcast in order to

Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2023Fourth Quarter 2023 · Total revenue increased 14 per cent, 15 per cent at constant exchange rates, (CER)[ii], to SEK 6,844 M (5,991) · Haematology revenue increased 21 per cent at CER to SEK 3,640 M (3,025), driven by sales of Vonjo[®] of SEK 322 M, strong sales of SEK 1,323 M for Elocta[®], growth for Doptelet[®] excluding China of 59 per cent at CER and sales of Aspaveli[®]/Empaveli[®] of SEK 186 M · Immunology revenue increased 10 per cent at CER to SEK 2,905 M (2,643), driven by

Earnings upgrade - MindArk's net sales and profit after financial items increase significantly in Q4 2023

MindArk PE AB (publ) ("MindArk" or the "Company") expects to report results for the fourth quarter of 2023 that are higher than current market expectations. The Company estimates that net sales for the fourth quarter of 2023 will amount to approximately 45-47 MSEK. This represents an increase of approximately 55-61 percent compared to the same period last year. Operating profit for Q4 2023 is estimated to amount to approximately 25-27 MSEK, which corresponds to an increase of approximately 140-160 percent compared to the same period last year. Profit after financial items is estimated at

Transaction in Own Shares

    08 February 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |07/02/2024|+----------------------------------------------------------

Orexo Interim Report Q4 2023, incl. Full Year Report

Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights›     Total net revenues of SEK 166.0 m (156.1)›     EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 23.4 m (-0.1) ›     Net earnings of SEK -18.6 m (-91.8)›     US Pharma segment (Zubsolv® US) net revenues of SEK 151.3 m (142.6), in local currency USD 14.2 m (13.3), US Pharma EBIT of SEK 75.4 m (77.0)›     Cash flow from operating activities of SEK -2.6 m (-48.9), cash and invested funds of SEK 171.0 m (351.9)›     Earnings per

Targeted forest protection is in the interest of nature, forest owners and the forest industry

Safeguarding the biodiversity of forest nature requires, in addition to forest protection, the promotion of practices that strengthen the state of nature in commercial forests. Metsä Group has set a goal of verifiably strengthening the state of nature by 2030. "Forest protection and strengthening the state of nature in commercial forests support each other. It is important that the boundaries of protected areas and commercial forests become clearer than at the moment, as it also stabilizes the operating environment for wood procurement and forest ownership," says Ilkka Hämälä, President

Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease

Lund, Sweden — 8 February 2024 — Camurus (NASDAQ STO: CAMX) today announces completed enrollment in the randomized, double-blind, placebo-controlled, multicenter Phase 2/3 study, POSITANO, evaluating the efficacy and safety of the company’s octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease (PLD). PLD is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver, which can cause severe symptoms and result in impaired quality of life for patients. An estimated 37,000 patients in the US and EU are today living

Humana reports fourth quarter and full year 2023 results

Strong performance from the Group in 2023Fourth quarter, October–December 2023 · Net revenue was SEK 2,396 million (2,438), a decrease of 2 percent. · Organic growth was -2.5 percent (5.5). Organic growth excluding Personal Assistance was 7.8 percent (9.7). · Operating profit amounted to SEK 85m (127), a decrease of 33 percent. Adjusted operating profit amounted to SEK 89m (89). Adjusted operating profit excluding Personal Assistance amounted to SEK 78m (60), an increase of 30 percent. · Net profit after tax for the period amounted to SEK 8m (59). · Earnings per share

Bactiguard Holding AB’s year-end report 2023

Stable fourth quarter marking the end of a challenging yearFourth quarter 2023 (October – December) · Total revenues amounted to SEK 61.3 (72.2) million, a decrease of 15.0 %. Net sales amounted to SEK 56.3 (61.3) million. Adjusted for the currency effect, net sales decreased by 9 %. · Operating loss amounted to SEK 23.8 (13.3) million, a decrease of SEK 10.5 million. · EBITDA amounted to SEK -4.2 (-1.1) million. · Net loss for the period amounted to SEK 27.2 (14.2) million. · Loss per share, before and after dilution, amounted to SEK 0.78 (0.40). · Cash flow from

Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

  Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds   VANCOUVER, British Columbia, 08 February 2024 (GLOBE NEWSWIRE) – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company’s MYCO-005 and MYCO-006 families.

Strong result for Lantmännen – new record dividend to Swedish farmers

Lantmännen’s result for 2023, after net financial items and adjusted for items affecting comparability, amounted to 2 462 MSEK – a slight decline compared to the previous year’s record result of 2 536 MSEK.”Despite an unsettled geopolitical situation and a weaker economy, Lantmännen delivered a strong result for the full year of 2023. In particular, the Energy Sector, Swecon Business Area and our international businesses in Lantmännen Unibake reported very good results for the year, while the Swedish food operations had a much tougher time,” says Magnus Kagevik, Lantmännen’s Group President

AcadeMedia acquires Touhula in Finland

AcadeMedia has signed an agreement to acquire all shares in Touhula Päiväkodit. The acquisition includes 113 preschools with about 7,700 children in Finland and is in line with AcadeMedia’s strategy to grow internationally. Touhula had a turnover in 2023 of about EUR 100 million and EBIT of about EUR 3 million. The transaction is expected to be completed on March 1st, 2024. - For a long time we have seen Finland as an attractive country for Academedia and we are delighted to have found a good partner there, says Katarina Wilson, acting CEO of AcadeMedia. In the past few years, Touhula

Neste's Financial Statements Release 2023

Neste Corporation, Financial Statements Release, 8 February 2024 at 9 a.m. (EET) Strong end for the year, cash flow the highlight in 2023 Year 2023 in brief: · Comparable EBITDA totaled EUR 3,458 million (EUR 3,537 million) · EBITDA totaled EUR 2,548 million (EUR 3,048 million) · Cash flow before financing activities totaled EUR 751 million (EUR -390 million) · Comparable return on average capital employed (Comparable ROACE) was 23.9% over the last 12 months (30.1%) · Leverage ratio was 22.7% at the end of December (31 Dec 2022: 13.9%) · Comparable earnings per

Prostatype Genomics acquires CLIA Certificate to facilitate rapid US market launch with a significantly stronger financial outlook

Prostatype Genomics AB ("Prostatype Genomics" or "the Company") announces that its wholly-owned US subsidiary Prostatype Genomics Inc. has acquired a CLIA Certificate in its own name. Together with the announced CLIA laboratory agreement with Research Dx, this will enable the Company to enter the US prostate cancer market with its prognostic biomarker test Prostatype® upon accreditation from the CAP (College of American Pathologists) and formal technical validation of the Prostatype® test services. Prostatype Genomics expects to achieve these remaining steps and to initiate clinical use of

Outokumpu financial statement release 2023: Solid adjusted EBITDA in 2023 in a weaker stainless steel market

Outokumpu OyjFinancial statements releaseFebruary 8, 2024 at 9.00 am EETOutokumpu financial statement release 2023: Solid adjusted EBITDA in 2023 in a weaker stainless steel market Highlights in Q4 2023   •        Stainless steel deliveries were 450,000 tonnes (450,000 tonnes)*. •        Adjusted EBITDA amounted to EUR 72 million (EUR 110 million). •        EBITDA was EUR 15 million (EUR 103 million). •        ROCE amounted to -2.1% (22.6%). •        Operating cash flow was EUR 236 million (EUR 289 million incl. discontinued operations). •        Net debt amounted

Realisation of Kesko's share-based commitment and incentive plan PSP 2022-2025

Kesko Corporation’s Board of Directors has decided, based on the fulfilment of the performance criteria for the 2022 and 2023 performance periods of the share-based commitment and incentive plan PSP 2022-2025, to grant a total of 199,654 Kesko B shares held by the company as treasury shares to the members of management and other key persons who were included in the target group for the plan. The share numbers represent gross earnings, from which the applicable taxes are deducted, and the remaining net amount is paid to the participants in shares.The share plans in Kesko’s share-based

Fiskars Corporation offers the ownership plan for the company’s management to new participants

Fiskars CorporationStock exchange releaseFebruary 8, 2024 at 9.00 a.m. EET Fiskars Corporation offers the ownership plan for the company’s management to new participants On 7 February 2023, it was announced that the Board of Directors of Fiskars Corporation (Board) had decided to launch the Fiskars Ownership Plan 2023 (Plan) directed to the company’s President and CEO, Group Leadership Team and certain key employees determined by the Board. The Board has now resolved to offer the Plan to a few additional participants. In the Plan, the participants are given an opportunity to

MEKO awarded bronze medal in renowned sustainability assessment

MEKO has been awarded a bronze medal by EcoVadis, the world's most trusted provider of business sustainability ratings, for its sustainability performance and achievements. Scoring well-above industry averages across all categories, MEKO is in the top 35 percent of assessed companies.MEKO has been practicing principles of sustainability for over 50 years by repairing and prolonging the life of car-related products. With circularity becoming an increasingly important part of the business, MEKO has intensified its sustainability efforts. Since 2019, MEKO has reported its greenhouse gas

New periods to start within the share-based long-term incentive programs of Fiskars Group

Fiskars CorporationStock exchange releaseFebruary 8, 2024 at 08.55 a.m. EET New periods to start within the share-based long-term incentive programs of Fiskars Group The Board of Directors of Fiskars Corporation has approved the launch of new periods for the years 2024–2026 within the Performance Share Plan and Restricted Share Plan, which form a part of Fiskars Group’s remuneration program for its key employees. The aim of the plans is to support the implementation of the company’s strategy and drive profitable growth and to align the objectives of key employees with the

Fiskars Corporation’s directed share issue without consideration based on the Restricted Share Plan

Fiskars CorporationStock Exchange ReleaseFebruary 8, 2024 at 08.50 a.m. EET Fiskars Corporation’s directed share issue without consideration based on the Restricted Share Plan The Board of Directors of Fiskars Corporation has decided on a directed share issue without consideration based on Fiskars’ Restricted Share Plan in order to pay the share rewards for the restriction period 2021–2023. In the share issue, 10,037 treasury shares are issued without consideration to the key personnel participating in the restriction period 2021–2023, in accordance with the terms and

Mineral Resources and Mineral Reserves 2023

“Increased Mineral Reserves in the Boliden Area has added equivalent to almost two years of production which is important for us. Also, exploration continues to give good results in Nautanen north of Aitik where we are working to eventually secure an environmental permit,” says Stefan Romedahl, President Boliden Mines. The cost of exploration in 2023 was SEK 853 m (770). AitikIn Aitik, Liikavaara is just about to come into production. Liikavaara is a part of Aitik Mineral Resource and Mineral Reserve and will be included in the production from 2024. Exploration and evaluation are

Improved margin in a challenging market

In the fourth quarter 2023, Inwido strengthens the gross margin for the fourth quarter in a row, improves cash flow, and ends the year with continued low debt despite the largest acquisition to date being completed in year. The results demonstrate the strenght of the business model and enable continued investments going forward despite challenging market conditions.During the fourth quarter, net sales decreased by 13%, organically -21%, mainly linked to the reduced volumes in new construction in Sweden and Finland. Operating EBITA amounted to SEK 290 million (315), while the operating EBITA

Boliden’s fourth quarter: Good cash flow despite intensive investment period

Revenues for the fourth quarter were SEK 20,754 m (23,577) and operating profit excluding revaluation of process inventory was SEK 2,017 m (3,190). Free cash flow totaled SEK 1,663 m (3,520), despite a record investment level.“I am happy to see several quarterly records in our smelting operations as well as good development in our investment projects. On top of that we are of course pleased with the underlying cash flow during the quarter,” says Mikael Staffas, President and CEO. The operating profit for Boliden Mines decreased to SEK 985 m (1,512) compared to last year but increased by

There are no items matching the current filter
There are no more items matching the current filter
Back to top